Aug 2026· Immunological Investigations· pp.
1-18
· 0 citations· 19 references
Medicine
TL;DR
Numb participates in coordinating inflammatory and fibrotic responses in IPF and may act as a regulatory mediator in inflammation - fibrosis coupling and may act as a regulatory mediator in inflammation - fibrosis coupling.
Abstract
Background
In idiopathic pulmonary fibrosis (IPF), inflammatory signaling and fibrotic remodeling often coexist, yet the mechanism linking these processes remains unclear. Numb, a cell fate determinant protein, has been implicated in tissue remodeling but its role in inflammation - fibrosis coupling is not well defined.
Methods
Public transcriptomic datasets were analyzed to assess NUMB expression patterns and associated pathways. A bleomycin (BLM)-induced mouse model was used for in vivo validation. In vitro, MRC-5 fibroblasts were stimulated with IL-1β and TGF-β1, alone or in combination, followed by Numb siRNA intervention. Cell viability, migration, cytokine secretion, and fibrosis-related protein expression were evaluated.
Results
Transcriptomic analysis showed a non-significant but consistent upward trend of NUMB in IPF tissues (p = .18), with pathway-level enrichment in inflammatory and extracellular matrix processes. In BLM-treated mice, IL-1β and TGF-β1 levels were significantly increased (both p < .001), accompanied by upregulation of Numb (p < .05), α-SMA, and Collagen I (both p < .001). In vitro, IL-1β and TGF-β1 synergistically enhanced cell viability and migration (both p < .001), as well as protein expression (p < .001). Numb silencing reduced cytokine secretion (p < .001), cell activation (p < .05-0.001), and fibrosis-related protein expression (p < .001).
Conclusion
Numb participates in coordinating inflammatory and fibrotic responses in IPF and may act as a regulatory mediator in inflammation - fibrosis coupling.
The TGF-β1/TWIST2/TPI1 signaling axis is defined as an important regulator of pathogenic fibroblast behavior and pro-fibrotic responses through transcriptional control of TPI1, highlighting its potential as a therapeutic target for IPF.
Jiawei Chen, Yu Li, Kai Fu et al.· Cellular Signalling· 0 citations
A CD28-JAK1/STAT6-Th2-monocyte-derived alveolar macrophage pathway is defined as a mechanistic driver of pulmonary fibrosis and nominate CD28 and STAT6 as actionable immunologic targets that could complement existing antifibrotic therapies.
Yudai Miyashita, T. Kaiho, Raul Piseaux Aillon et al.· American Journal of Respirat...· 0 citations
Results indicate LGMN promotes pulmonary fibrosis by activating the p38 MAPK pathway to regulate EndMT, suggesting its potential as a therapeutic target for pulmonary fibrosis.
IL-4Rα-mediated signaling is identified as a promising intervention point in pulmonary fibrosis and support further investigation of dupilumab as a candidate therapy for fibrotic lung diseases.
Qi Chen, Yu-Pei Zhang, Shi-Yang Wang et al.· Lung· 0 citations
It is suggested that DSP may function as a regulator of alveolar epithelial homeostasis and extracellular matrix remodeling in an in vitro epithelial model, and a candidate pathway that may contribute to ECM dysregulation in IPF is identified.
Gen and protein expression analyses demonstrated that SNG dose-dependently attenuated the bleomycin-induced inflammatory and fibrotic marker expression, and mechanistic investigations demonstrated that SNG exerts its anti-inflammatory and antifibrotic effects partly through activation of AMPK signaling.
Suriya Panneerselvam, J. S, Anoop Kishore et al.· ACS Pharmacology & Translati...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.